Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE PV: Ropeginterferon in PV
NCT05481151Phase 3Active, not recruiting
- Sponsor
- PharmaEssentia
- Start
- Oct 2022
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ropeginterferon alfa-2b in polycythemia vera (PV) (2 arms), sponsored by PharmaEssentia. Primary endpoint: Complete Hematologic Response at 24 weeks. Started Oct 2022; status: active, not recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT05481151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481151.